Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M153,099Revenue (TTM) $M39,385Net Margin (%)11.7Altman Z-Score3.1
Enterprise Value $M166,020EPS (TTM) $1.6Operating Margin %18.4Piotroski F-Score7
P/E(ttm)33.9Beneish M-Score-2.8Pre-tax Margin (%)14.3Higher ROA y-yN
Price/Book3.510-y EBITDA Growth Rate %3.8Quick Ratio1.4Cash flow > EarningsY
Price/Sales4.05-y EBITDA Growth Rate %9.2Current Ratio1.6Lower Leverage y-yY
Price/Free Cash Flow14.3y-y EBITDA Growth Rate %-45.4ROA % (ttm)4.5Higher Current Ratio y-yY
Dividend Yield %3.3PEG3.7ROE % (ttm)10.1Less Shares Outstanding y-yY
Payout Ratio %111Shares Outstanding M2,768ROIC % (ttm)10.6Gross Margin Increase y-yY

Gurus Latest Trades with MRK

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
MRKRichard Pzena 2016-03-31 Buy 0.3%$48.59 - $53.32
($51.31)
$ 55.318%New holding921,365
MRKJoel Greenblatt 2016-03-31 Add0.29%$48.59 - $53.32
($51.31)
$ 55.318%Add 65.71%1,248,557
MRKKahn Brothers 2016-03-31 Reduce-0.24%$48.59 - $53.32
($51.31)
$ 55.318%Reduce -2.52%985,419
MRKT Rowe Price Equity Income Fund 2016-03-31 Reduce-0.22%$48.59 - $53.32
($51.31)
$ 55.318%Reduce -16.17%4,702,900
MRKVanguard Health Care Fund 2016-03-31 Reduce-0.18%$48.59 - $53.32
($51.31)
$ 55.318%Reduce -3.46%48,728,100
MRKNWQ Managers 2016-03-31 Sold Out -0.06%$48.59 - $53.32
($51.31)
$ 55.318%Sold Out0
MRKKen Fisher 2016-03-31 Reduce-0.01%$48.59 - $53.32
($51.31)
$ 55.318%Reduce -1.82%6,698,235
MRKMario Gabelli 2016-03-31 Reduce-0.01%$48.59 - $53.32
($51.31)
$ 55.318%Reduce -15.38%118,145
MRKCharles Brandes 2016-03-31 Reduce-0.01%$48.59 - $53.32
($51.31)
$ 55.318%Reduce -0.42%3,000,058
MRKDodge & Cox 2016-03-31 Reduce$48.59 - $53.32
($51.31)
$ 55.318%Reduce -0.08%24,543,704
MRKBarrow, Hanley, Mewhinney & Strauss 2016-03-31 Add$48.59 - $53.32
($51.31)
$ 55.318%Add 0.03%26,663,511
MRKFirst Eagle Investment 2016-03-31 Add$48.59 - $53.32
($51.31)
$ 55.318%Add 106.55%16,090
MRKDavid Dreman 2016-03-31 Buy $48.59 - $53.32
($51.31)
$ 55.318%New holding710
MRKRuane Cunniff 2016-03-31 Reduce$48.59 - $53.32
($51.31)
$ 55.318%Reduce -2.00%4,894
MRKJoel Greenblatt 2015-12-31 Add0.43%$49.47 - $55.53
($52.9)
$ 55.315%Add 12793.07%753,471
MRKT Rowe Price Equity Income Fund 2015-12-31 Reduce-0.21%$49.47 - $55.53
($52.89)
$ 55.315%Reduce -14.63%5,610,000
MRKCharles Brandes 2015-12-31 Add0.17%$49.47 - $55.53
($52.9)
$ 55.315%Add 7.90%3,012,572
MRKBarrow, Hanley, Mewhinney & Strauss 2015-12-31 Add0.12%$49.47 - $55.53
($52.9)
$ 55.315%Add 5.86%26,655,176
MRKVanguard Health Care Fund 2015-12-31 Add0.08%$49.47 - $55.53
($52.9)
$ 55.315%Add 1.47%50,476,700
MRKPrem Watsa 2015-12-31 Sold Out -0.05%$49.47 - $55.53
($52.9)
$ 55.315%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

MRK is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


MRK: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Golestani ClarkEVP & Chief Info Officer 2016-05-20Sell39,877$54.790.95view
Holston Michael JEVP, General Counsel 2016-05-10Sell100,021$54.51.49view
FRAZIER KENNETH CChairman, President & CEO 2016-04-14Sell131,040$56.11-1.43view
WEEKS WENDELL PDirector 2015-11-04Sell5,000$55.53-0.4view
AMBROSE ADELE DSr.V-P & Chief Comuns Officer 2015-10-29Sell37,313$55.080.42view
FRAZIER KENNETH CChairman, President & CEO 2015-10-29Sell18,666$54.691.13view
WENDELL PETER CDirector 2015-10-28Sell5,000$54.850.84view
Golestani ClarkEVP & Chief Info Officer 2015-07-31Sell31,831$59.09-6.4view
Schechter Adam HEVP & Pres-Global Human Health 2015-05-11Sell10,634$60.44-8.49view
Gerberding Julie L.EVP Strat Comm, Gl Pub Policy 2015-05-08Sell38,368$60.99-9.31view

Press Releases about MRK :

Quarterly/Annual Reports about MRK:

News about MRK:

Articles On GuruFocus.com
Market Indexes Higher With Volatility Lower May 25 2016 
The PBM Empire Strikes Back May 10 2016 
U.S. Stocks Trade Flat at Start of Week May 09 2016 
Market Indexes Flat as Economic Indicators Still Point Lower May 08 2016 
UnitedHealth’s Obamacare Changes to Affect Healthcare Sector Apr 27 2016 
Merck CEO Kenneth Frazier Sells 131,040 Shares Apr 15 2016 
Manning & Napier Sells Chunks of Stakes in GE, Eli Lilly, Merck Mar 29 2016 
An Attempt to Value Valeant Just for Fun Mar 23 2016 
Whole Foods' Green Initiatives Will Pay Off for Investors Mar 22 2016 
Amgen: Should I Just Sit and Wait? Mar 18 2016 

More From Other Websites
Merck to Develop Next-Generation Purification Processes with International Vaccine Institute Jun 28 2016
The Largest Drug Pipelines Will Surprise You Jun 27 2016
Merck Gets CHMP Positive Opinion For KEYTRUDA For Advanced Non-Small Cell Lung Cancer Treatment Jun 27 2016
Short Sellers Increase Bets Against Major Pharmaceutical Stocks Jun 27 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced... Jun 27 2016
6:03 am Merck announces positive opinion from the CHMP recommending approval of KEYTRUDA for the... Jun 27 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA® (pembrolizumab) for the Treatment of Advanced... Jun 27 2016
Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29 Jun 24 2016
Merck to Hold Second-Quarter 2016 Sales and Earnings Conference Call on July 29 Jun 24 2016
German pharma lobby says EU drug regulator must leave London Jun 24 2016
German pharma lobby says EU drug regulator must leave London Jun 24 2016
Sanofi's Likely Sweetener for Medivation Panned Jun 23 2016
Incyte Reports Epacadostat Combination Study Initiation Jun 23 2016
What’s so ‘groundbreaking’ about Curis’ new cancer drug that just began human trials? Jun 22 2016
The Top Four Diabetes Best Sellers and One Oral Insulin Pill That May Threaten Them All Jun 22 2016
Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in... Jun 20 2016
Results of Phase 2 Study of Merck’s Investigational Beta-Lactamase Inhibitor Relebactam in... Jun 20 2016

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)